NATO Secretary General Mark Rutte said Friday’s summit between President Donald Trump and Russian President Vladimir Putin in Alaska will be an important test for Putin.
ABC News: Top Stories
NATO Secretary General Rutte says Trump-Putin summit is about ‘testing Putin’
August 10, 2025By
Consensus Statement on Universal Chemosensory Testing Calls for Better Standardization, Infrastructure, and Education in the Field
June 19, 2025By
A new white paper, published in Chemical Senses, summarizes recommendations on the need for increased chemosensory testing; barriers to its broad implementation, along with opportunities for addressing them; and priorities for making chemosensory testing on taste and smell health a common part of everyday health care. Conference co-organizing institutions with the host, the Monell Chemical Senses Center were the Massachusetts General Hospital, The Ohio State University, and the University of Florida.
Newswise: Latest News
Which test is best? Frequent versus infrequent testing for the Omicron variant of COVID-19
January 31, 2023By
Testing plays a crucial role in humanity’s strategy to mitigate the effects of widespread COVID-19 infection. However, given multiple options for testing and the emergence of the highly contagious Omicron variant, how do we choose which test to use?
Newswise: Latest News
Chest Pain Patients Benefit from Precision Diagnostic Testing Approach
November 7, 2022By
A study comparing two approaches for diagnosing heart disease found that a risk analysis strategy is superior to the usual approach of immediately performing functional tests or catheterization for low- to intermediate-risk patients with new-onset chest pain.
Newswise: Latest News
Some lab techs refuse to take blood from possible monkeypox patients, raising concerns about stigma and testing delays
August 6, 2022By
Many technicians at Labcorp and Quest Diagnostics, two of the largest commercial labs in the US, have been refusing to draw blood from patients who might have monkeypox, CNN has learned.
CNN.com – RSS Channel – Health
Trump knew testing Covid-19 vaccines would take months, Woodward book shows
November 23, 2021By
President Donald Trump knew back in the spring that it would probably take a year to develop a coronavirus vaccine, according to interviews with journalist Bob Woodward.
College hits unvaccinated students with $750 fee for COVID-19 testing
August 13, 2021By
Despite the raging virus, vaccine mandates have become a hot button issue.
ABC News: Top Stories
Trump knew testing Covid-19 vaccines would take months, Woodward book shows
September 23, 2020By
President Donald Trump knew back in the spring that it would probably take a year to develop a coronavirus vaccine, according to interviews with journalist Bob Woodward.
Dwayne ‘The Rock’ Johnson shares his tips to prevent COVID-19 after testing positive
September 3, 2020By
Dwayne Johnson revealed in an Instagram video that he and his family members have tested positive for COVID-19.
ABC News: Top Stories
Diabetes Health Type 1 &2: Novo’s Weekly Insulin Now in Phase II Testing
July 18, 2020By
Diabetes Health Staff
Even though the annual Scientific Sessions of the American Diabetes Association (June 12-16) will be “virtual,” with presenters and attendees spread around the world and Zooming in via their computers, there are already some tantalizing hints about new drug development.
Novo Nordisk researchers will present an update on insulin icodec, a long-acting basal insulin they are developing that has a half life of 196 hours—8+ days. The drug, which has now entered phase II* testing, offers the possibility of a once weekly insulin dose for people with type 2 diabetes.
The insulin is very concentrated, which means that even though it is injected once a week, the injection is not a multiple of the volume of daily injections a type 2 takes.
Novo currently is comparing insulin icodec’s performance against insulin glargine U100, Sanofi-Aventis’s Lantus®, which is one of the most prescribed basal insulins in the world.
Icodec will enter a market where Novo and Sanofi are already competing for share with two extremely powerful basal insulins, Tresiba® (insulin degludec) from Novo, and Toujeo® (insulin glargine U300) from Sanofi. Both insulins provide 24-hour effectiveness, and for now are the heaviest hitters in the diabetes drug market.
In a way, insulin icodec is the logical next step in basal insulins. With Tresiba® and Toujeo® emerging as the first 24-hour basals, the only room for improvement and innovation is to introduce even longer lasting drugs.
At this point in icodec’s development, its eventual cost and acceptance by healthcare insurers and providers won’t be determined for at two or three years. Still, it’s something to look forward to for type 2s who are tired of the unrelenting need for daily insulin injections—even ones that can last an entire day.
A GLP-1 in Pill Form
Novo also plans to present data on Rybelsus® (semaglutide) is the first GLP-1 receptor agonist in the market. GLP-1s spur type 2 pancreas’s into making more insulin, while at the same time producing fewer incidence of hypoglycemia than, say, sulfonylureas . Rybelsus’s claim to fame is that it is the first GLP-1 to enter the market in pill form (7 mg and 14 mg doses). Other brands of GLP-1s on the market include, among others, Byetta®, Victoza®, Trulicity®, and Ozempic®.
The post Diabetes Health Type 1 &2: Novo’s Weekly Insulin Now in Phase II Testing appeared first on Diabetes Health.
